Stem Cell Organoid Therapy Advances to Crohn's Disease Trials
Organoid Science Enters Clinical Trials for Crohn's Disease Treatment
2026.03.16Updated 29d ago
Organoid Science (476040) announced on the 16th that its autologous adult stem cell-derived intestinal organoid therapy 'ATORM-C' has received Phase 1 Investiga
AI SummaryPowered by AI
Organoid Science has initiated Phase 1 clinical trials for ATORM-C, an autologous adult stem cell-derived intestinal organoid therapy targeting Crohn's disease treatment. The breakthrough represents a significant milestone in regenerative medicine, offering potential for personalized organ replacement approaches. This advancement could reshape inflammatory bowel disease management strategies.
Original Article
Read full article on sourceorganoid scienceatorm-cstem cell therapycrohn's diseaseregenerative medicinephase 1 trialsintestinal organoidsclinical trialsorganoidscience
Explore More
Related News
Monmouth College Enhances Computer Science Program
River Cities’ Reader · 2026.04.14
The 9 Best Science Podcasts
2026.04.14
Genetic Science Could Extend Human Lifespans
2026.04.14
Simplifying Science: ANRF's SARAL AI Initiative
Devdiscourse · 2026.04.14
Spot solid science and avoid fake claims
CBC · 2026.04.14
President of Chulalongkorn University in Thailand visits Science Tokyo | Science Tokyo
2026.04.14